On December 10, 2020, Dr. David will give a short presentation to the Vaccines and Related Biological Products Advisory Committee (VRBPAC) during their meeting to discuss Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine.
At the committee meeting, Dr. David will stress the importance of the FDA coordinating with healthcare providers to discuss aspects of the vaccine evaluation process where it appears rigor and transparency are lacking, and will make specific recommendations for how the FDA can actively address these concerns. He believes that without addressing these process shortcomings, not only will vaccine hesitancy likely persevere, but confidence in the integrity of the FDA’s process will continue to be undermined.
– ONLINE PRESENTATION –
Dr. David’s presentation to the Committee will take place Thursday, December 10, 2020, sometime between 12:00pm – 1:00pm ET. It will be available to view at either of these links:
FDA Webcast
– or –
YouTube
– WRITTEN COMMENTS –
In advance of his presentation, Dr. David submitted the following written comments to the committee: